首页> 美国卫生研究院文献>other >The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers 2012–2014
【2h】

The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers 2012–2014

机译:2012-2014年来自中国五个血液中心的被人类免疫缺陷病毒1感染的献血者的感染分期基因型分布和耐药性突变情况

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The increasing complexity and diversity of the human immunodeficiency virus-1 (HIV-1) infections challenge the disease control and anti-retrovirus treatment in China. The infection stages and molecular characteristics of HIV-1 from infected Chinese blood donors were examined to shed light on the HIV genotype distribution and the status of drug resistance mutations (DRMs) in the changing HIV epidemic in China. Western blot (WB) confirmed HIV-1 positive plasma samples were collected from blood donors at five Chinese blood centers from April 16, 2012, through June 30, 2014. The HIV infection stages were determined using the Lag-avidity assay. HIV Pol regions including whole protease and partial reverse transcriptase (RT) were amplified and sequenced to establish the profile of genotype distribution and drug resistance mutations (DRMs). Viral loads were determined using the ROCHE COBAS system. Of the 259 HIV-1 positive samples tested by the Lag-avidity assay, 23.6% (61/259) were identified as recent infections. A total of 205 amplified sequences displayed the following genotype distributions: circulating recombinant form (CRF) 07_BC (61.5%), CRF08_BC (8.3%), CRF01_AE (20%), B (6.3%), and 01B (3.9%). There was no significant difference in genotype distribution between recent and long-term infections. 31 DRMs were identified from 27 samples including four protease inhibitors (PIs) accessory DRMs, two PIs major DRMs (M46I), two nucleoside RT inhibitors DRMs (K219R and K70Q), and 23 nonnucleoside RT inhibitors DRMs. 27 samples had DRMs, yielding a drug resistance prevalence of 13.2% (27/205). Our findings provide important information for developing strategies for comprehensive HIV control and improving anti-retroviral treatment in China.
机译:人类免疫缺陷病毒1(HIV-1)感染的复杂性和多样性日益增加,对中国的疾病控制和抗逆转录病毒治疗提出了挑战。检查了来自中国献血者的HIV-1的感染阶段和分子特征,以揭示中国不断变化的HIV流行中的HIV基因型分布和耐药性突变(DRM)的状况。 Western blot(WB)证实,自2012年4月16日至2014年6月30日,从五个中国血液中心的献血者那里采集了HIV-1阳性血浆样品。使用Lag亲和力测定法确定了HIV感染的阶段。扩增并测序包括完整蛋白酶和部分逆转录酶(RT)的HIV Pol区,以建立基因型分布和耐药性突变(DRM)的分布图。使用ROCHE COBAS系统确定病毒载量。在Lag亲和力测定法测试的259个HIV-1阳性样本中,有23.6%(61/259)被鉴定为近期感染。总共205个扩增序列显示出以下基因型分布:循环重组形式(CRF)07_BC(61.5%),CRF08_BC(8.3%),CRF01_AE(20%),B(6.3%)和01B(3.9%)。在近期和长期感染之间,基因型分布没有显着差异。从27个样品中鉴定出31个DRM,包括四个蛋白酶抑制剂(PI)辅助DRM,两个PI主要DRM(M46I),两个核苷RT抑制剂DRM(K219R和K70Q)和23个非核苷RT抑制剂DRM。 27个样本具有DRM,耐药率达13.2%(27/205)。我们的发现为制定全面的HIV控制策略和改善中国的抗逆转录病毒治疗提供重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号